<< Вернуться к списку статей журнала

Том 8 №2 2006 год - Нефрология и диализ

Контраст-индуцированная нефропатия: патогенез, факторы риска, стратегия профилактики (часть II)

Волгина Г.В.

Аннотация: Пациент 62 лет с хроническим гломерулонефритом и артериальной гипертензией с 40-летнего возраста страдал ИБС: стенокардией напряжения ФК II-III. Перенес инфаркт миокарда (в 48 и 61 год), осложнившийся хронической постинфарктной аневризмой передне-перегородочной и верхушечной областей левого желудочка сердца и развитием хронической сердечной недостаточности II ФК (NYHA). Больного продолжала беспокоить стенокардия, в связи с чем ему было предложено проведение коронарной ангиографии с целью дальнейшего оперативного лечения (аорто-коронарное шунтирование). Перед процедурой коронарной ангиографии уровни Cr в сыворотке крови 397 мкмоль/л (СКФ по Кокрофту-Голту 16 мл/мин/1,73 м ), гемоглобина - 94 г/л. Через двое суток после проведения ангиографического исследования уровень Cr в сыворотке крови превысил 1000 мкмоль/л и стали нарастать симптомы хронической сердечной недостаточности: появились одышка в покое, тахикардия, влажные мелкопузырчатые хрипы в легких, отеки ног, двухсторонний гидроторакс, увеличение размеров печени. Проводившееся лечение гемодиализом не привело к восстановлению исходной функции почек, и через 9 месяцев пациент умер при явлениях прогрессирующей сердечной недостаточности. Несомненно, резкое ухудшение состояния, приведшее к летальному исходу, было спровоцировано введением рентгеноконтрастного средства при коронарографическом исследовании, развитием ОПН на фоне предшествующего нарушения функции почек. Учитывая трудности, возникающие при обследовании и лечении подобных пациентов, в данном обзоре поставлена задача проанализировать современные данные снижения риска контраст-индуцированной нефропатии.

Для цитирования: Волгина Г.В. Контраст-индуцированная нефропатия: патогенез, факторы риска, стратегия профилактики (часть II). Нефрология и диализ. 2006. 8(2):176-183. doi:

Весь текст

Ключевые слова: контраст-индуцированная нефропатия, факторы риска, методы профилактики

Список литературы:

1. Abizaid A.S., Clark C.E., Mintz G.S. et al. Effects of dopamine and aminophylline on contrast induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 1999; 83: 260-263.
2. Agrawal M., Stouffer G.A. Contrast induced nephropathy after angiography. Am Med Sci 2002; 323(5): 252-255.
3. Allaqaband S., Tumuluri R., Malik A.M. et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc Intervent 2002; 57: 279-283.
4. Aspelin P., Aubry P., Fransson S.G. et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348(6): 491-489.
5. Barrett B.J., Parfrey P.S. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994; 331: 1449-1450.
6. Barrett B.J. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5: 125-137.
7. Boccalandro F., Amhad M., Smalling R.W., Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Cathet Cardiovasc Intervent 2003;58: 336-341.
8. Briguori C., Manganelli F., Scarpato P. et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002; 40: 298-303.
9. Chalmers N., Jackson R.W. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-703.
10. Cox C.D., Tsikouris J.P. Preventing contrast nephropathy: what is the best strategy? A review of the literature. J Clin Pharmacol 2004; 44: 327-337.
11. Diaz-Sandoval L.J., Kosowsky B.D., Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am Coll Cardiol 2002; 89(3): 356-358.
12. Erley C.M., Duda S.H., Rehfuss D. et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14: 1146-1149.
13. Erley C.M., Duda S.H., Schlepckow S. et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45: 1425-1431.
14. Esnault V.L. Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. Nephrol Dial Transplant 2002;17: 1362-1364.
15. Esplugas E., Cequier A., Gomez-Hospital J.A. et al. Comparative tolerability of contrast media used for coronary interventions. Drug Saf 2002; 25(15): 1079-1098.
16. Gare M., Haviv Y.S., Ben-Yehuda A. et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34: 1682-1688.
17. Gupta R.K., Kapoor A., Tewari S. et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51: 521-526.
18. Hans S.S., Hans B.A., Dhillon R., Dmuchowski C., Glover J. Effect of dopamine on renal function after arteriography in patients with preexisting renal insufficiency. Am Surg 1998; 64: 432-436.
19. Heyman S.N., Reichman J., Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999; 34: 685-691.
20. Huber W., Ilgmann K., Page M. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002; 223: 772-779.
21. Huber W., Jeschke B., Page M. et al. Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001; 27: 1200-1209.
22. Jones A., Haynes W., MacGilchrist A.J. et al. N-acetyl-cysteine (NAC) is a potent peripheral vasodilator [abstract]. Gut 1994; 35(Suppl. 5): S10.
23. Kapoor A., Sinha N., Sharma R.K. et al. Use of dopamine in prevention of contrast induced acute renal failure: a randomized study. Int J Cardiol 1996; 53: 233-236.
24. Kapoor, Kumar S., Gulati S. et al. The role of theophylline in contrast-induced nephropathy: a case-control study Nephrol Dial Transplant 2002; 17: 1936-1941.
25. Katholi R.E., Taylor G.J., McCann W.P. et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195: 17-22.
26. Kay J., Chow W.H., Chan T.M. et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553-538.
27. Kini A.S., Mitre C.A., Kamran M. et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89: 999-1002.
28. Kini A.S., Mitre C.A., Kim M., Kamran M. et al. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Cathet Cardiovasc Intervent 2002; 55: 169-173.
29. Koch J.A., Plum J., Grabensee B. et al. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? Nephrol Dial Transplant 2000; 15: 43-49.
30. Korr K.S., Reitman A. Renal implications of percutaneous coronary intervention. Semin Nephrol 2001; 21(1): 36-46.
31. Kurnik B.R., Allgren R.L., Genter F.C. et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31(4): 674-80.
32. Liss P., Carlsson P.O., Nygren A. et al. ET-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiologica 2003; 44: 111-117.
33. Maddox T.G. Adverse reactions to contrast material: recognition, prevention, and treatment. Am Fam Physician 2002;66: 1229-1234.
34. Madyoon H., Croushore L., Weaver D., Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Cathet Cardiovasc Intervent 2001; 53: 341-345.
35. Marenzi G., Marana I., Lauri G. et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349:1333-1340.
36. Mehran R., Aymong E.D., Nikolsky E. et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.
37. Merten G.J., Burgess W.P., Gray L.V. et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334.
38. Morcos S.K., Thomsen H.S., Webb J.A.W. and members of contrast media safety committee of the European Society of Urogenital Radiology (ESUR). Contrast media induced nephrotoxicity: A consensus report. Eur Radiol 1999; 9:1602-1613.
39. Muller C., Buerkle G., Buettner H. et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-336.
40. Murphy S.W., Barrett B.J., Parfrey P.S. Contrast nephropathy. J Am Soc Neprol 2000; 11: 177-182.
41. Neumayer H.H., Junge W., Kufner A., Wening A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989; 4: 1030-1036.
42. Rezkalla S.H. Contrast Nephropathy. Clinical Medicine 2003; (1): 301-304.
43. Rodicio J.L., Morales J.M., Ruilope L.M. Calcium antagonists and the kidney. Nephrol Dial Transplant 1990; 5: 81-86.
44. Rudnick M.R., Goldfarb S., Wexler L. et al. Nephrotoxicity of ionic and non-ionic contrast media in 1196 patients: a randomized trial. Kidney Int 1995; 47: 254-261.
45. Russo D., Testa A., Della Volpe L., Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990; 55: 254-257.
46. Shammas N.W., Kapalis M.J., Harris M. et al. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invas Cardiol 2001; 13: 738-740.
47. Shyu K.G., Cheng J.J., Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002; 40: 1383-1388.
48. Solomon R., Werner C., Mann D., D'Elia J., Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331(21): 1416-1420.
49. Spangberg-Viklund B., Berglund J., Nikonoff T. et al. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol 1996; 30: 63-68.
50. Stemer G., Frennby B., Kukus J., Nyman U. Does post-angiographic hemodialysis reduce the risk of contrast medium nephropathy? Scand Urol Nephrol 2000; 34: 323-326.
51. Stevens M, McCullough P, Tobin K. et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy. J Am Coll Cardiol 1999; 33: 403-411.
52. Stone G., McCullough P., Tumlin J. et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291.
53. Stone G.W., McCullough P., Tumlin J. et al. A prospective, randomized placebo-controlled multicenter trial evaluating fenoldopam mesylate for the prevention of contrast induced nephropathy: the CONTRAST trial [abstract]. J Am Coll Cardiol 2003; 41(6): 84A-85A.
54. Tepel M., van der Giet M., Schwarzfeld C. et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
55. Thomsen H.S., Morcos S.K. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. British Journal of Radiology 2003; 76: 513-518.
56. Trivedi H.S., Moore H., Nasr S. et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93(1): 29-34.
57. Tumlin J.A., Wang A., Murray P.T., Mathur V.S. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002; 143: 894-903.
58. Wang A., Holcslaw T., Bashore T.M. et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-1680.
59. Waybill M.M., Waybill P.N. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001; 12: 3-9.
60. Weinstein J.M., Heyman S., Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992; 62: 413-415.
61. Weisberg L.S., Kurnik P.B., Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-265.
62. Wilfling M., Kampf D., Jun M.S., Junge W. Nitrendipine and nephrotoxicity of non-ionic contrast media: a randomized controlled clinical trial. J Am Soc Nephrol 1991; 3: 671-679.

Другие статьи по теме

• Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности
• Кальцификация клапанов сердца у больных с терминальной хронической почечной недостаточностью
• К вопросу о значении специфических антигензависимых и неспецифических факторов в патогенезе хронической трансплантационной нефропатии
• Факторы риска кардиоваскулярных заболеваний у больных с хронической почечной недостаточностью